The increased knowledge about sST2 and ST2L actions on cardiovascular system led physicians to consider the assessment of plasma levels of sST2 as a novel marker of cardiovascular events and clinical conditions, above all related to heart failure and ischemic heart diseases [19,20]. The gene discussed is IL1RL1; the disease is coronary artery disorder.